A Phase 3 interventional study of bevacizumab and ranibizumab in Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration and Wet Macular Degeneration, sponsored by Outlook Therapeutics, Inc.. Completed at 50 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Outlook Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Wet Macular Degeneration with a site in United States — 7 open to participants now, 14 under way, 7 of them phase 3. Wet Macular Degeneration · United States.
Among the 49 studies in Wet Macular Degeneration with a site in United States, this one is the 17th largest by enrollment of the 45 interventional ones that give a count, is one of 10 that started in 2019, is one of 13 in phase 3, and was the 23rd registered.
93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.
Browse Wet Macular Degeneration studies →7 of the 49 studies in Wet Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:
EyeBiotech Ltd. · Sites in United States, Brazil, Colombia and 6 more countries
Ages 50+
EyeBiotech Ltd. · Sites in United States, Argentina, Australia and 9 more countries
Ages 50+
4D Molecular Therapeutics · Sites in United States, Argentina, Australia and 14 more countries
Ages 50+
4D Molecular Therapeutics · Sites in United States, Puerto Rico
Ages 50+
University of Iowa · Sites in United States
Ages 50–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Wet Macular Degeneration studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 22 · Phase 3 19 · Phase 4 4
First in 2006; this study’s year is marked. 10 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 228 is above the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.
Median enrollment 91 across the 45 interventional studies, 22 across the 4 observational. Of the 33 that completed or were terminated, 19 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 49 have an industry lead sponsor. The 10 most frequent:
Outlook Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Outlook Therapeutics, Inc. has 5 studies filed under Wet Macular Degeneration — fewer than ten, so there is no comparison to draw.
6 of the studies in Wet Macular Degeneration with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT06864988Phase 34D Molecular Therapeutics4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-06 |
| NCT07064759Phase 34D Molecular TherapeuticsSingle Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-11 |
| NCT04504123University of IowaMMP-9 Inhibition for Recalcitrant Wet AMD | 2026-12-31 |
| NCT051972704D Molecular Therapeutics4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 49 studies in Wet Macular Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.
93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.
This study's enrollment of 228 is above the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.
Browse Wet Macular Degeneration studies →Outlook Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Compared within Wet Macular Degeneration, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study eye must:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ONS-5010
Biological: bevacizumab
Biological: ranibizumab
1.25 mg, intravitreal injection
Also known as: ONS-5010
0.5mg, intravitreal injection
Proportion of Subjects Who Gain 15 or More Letters in Best Corrected Visual Acuity (BCVA)
BCVA to be assessed as letters read using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts. A positive change represents an improvement in visual acuity.
Time frame: 11 months
Mean Change in the Best Corrected Visual Acuity
BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.
Time frame: 11 months
Proportion of Participants Who Gain at Least 10 Letters in the Best Corrected Visual Acuity
BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.
Time frame: 11 months
Proportion of Participants Who Gain at Least 5 Letters in the Best Corrected Visual Acuity
BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.
Time frame: 11 months
Proportion of Participants Who Lose Fewer Than 15 Letters in the Best Corrected Visual Acuity
BCVA to be assessed as letters read using the ETDRS charts. A negative change represents a decrease in visual acuity.
Time frame: 11 months
Proportion of Participants With Visual-acuity Snellen Equivalent of 20/200 or Worse
Time frame: 11 months
| Milestone | Bevacizumab | Ranibizumab |
|---|---|---|
| Started | 113 | 115 |
| Completed | 103 | 95 |
| Not completed | 10 | 20 |
BCVA to be assessed as letters read using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts. A positive change represents an improvement in visual acuity.
| Participants | Bevacizumab | Ranibizumab |
|---|---|---|
| Proportion of Subjects Who Gain 15 or More Letters in Best Corrected Visual Acuity (BCVA) | 45 | 24 |
BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.
| letters | Bevacizumab | Ranibizumab |
|---|---|---|
| Mean Change in the Best Corrected Visual Acuity | 11.2 ± 12.19 | 5.8 ± 14.80 |
BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.
| Participants | Bevacizumab | Ranibizumab |
|---|---|---|
| Proportion of Participants Who Gain at Least 10 Letters in the Best Corrected Visual Acuity | 61 | 36 |
BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.
| Participants | Bevacizumab | Ranibizumab |
|---|---|---|
| Proportion of Participants Who Gain at Least 5 Letters in the Best Corrected Visual Acuity | 74 | 53 |
BCVA to be assessed as letters read using the ETDRS charts. A negative change represents a decrease in visual acuity.
| Participants | Bevacizumab | Ranibizumab |
|---|---|---|
| Proportion of Participants Who Lose Fewer Than 15 Letters in the Best Corrected Visual Acuity | 101 | 86 |
| Participants | Bevacizumab | Ranibizumab |
|---|---|---|
| Proportion of Participants With Visual-acuity Snellen Equivalent of 20/200 or Worse | 14 | 25 |
Collected over from enrollment to 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab | 3/113 (2.7%) | 14/113 (12.4%) | 31/113 (27.4%) |
| Ranibizumab | 2/115 (1.7%) | 16/115 (13.9%) | 34/115 (29.6%) |
| Event | Bevacizumab | Ranibizumab |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 1/113 | 0/115 |
| Aortic valve stenosisCardiac disorders | 1/113 | 0/115 |
| Bundle branch blockCardiac disorders | 1/113 | 0/115 |
| Myocardial infarctionCardiac disorders | 1/113 | 0/115 |
| DeathGeneral disorders | 1/113 | 0/115 |
| COVID-19Infections and infestations | 1/113 | 1/115 |
| Clostridium difficile infectionInfections and infestations | 1/113 | 0/115 |
| PneumoniaInfections and infestations | 1/113 | 0/115 |
| Urinary tract infectionInfections and infestations | 1/113 | 0/115 |
| Rib fractureInjury, poisoning and procedural complications | 1/113 | 0/115 |
| Event | Bevacizumab | Ranibizumab |
|---|---|---|
| Visual acuity reducedEye disorders | 3/113 | 17/115 |
| Conjunctival haemorrhageEye disorders | 10/113 | 3/115 |
| Urinary tract infectionInfections and infestations | 8/113 | 5/115 |
| Retinal haemorrhageEye disorders | 3/113 | 8/115 |
| Intraocular pressure increasedInvestigations | 7/113 | 1/115 |
| Age, Continuous(years) | Bevacizumab | Ranibizumab | Total |
|---|---|---|---|
| Mean | 78.8 ± 8.30 | 79.1 ± 8.49 | 78.9 ± 8.38 |
| Sex: Female, Male(Participants) | Bevacizumab | Ranibizumab | Total |
|---|---|---|---|
| Female | 67 | 69 | 136 |
| Male | 46 | 46 | 92 |
| Race (NIH/OMB)(Participants) | Bevacizumab | Ranibizumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 110 | 113 | 223 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Data will not be shared until all global regulatory filings are complete.
Ran from Jun 2019 to primary completion in Jun 2021, 23 months.
Results were first posted in Aug 2026, 5 years 1 month after primary completion. A results delay was requested in Nov 2021.
Of 16 phase 3 interventional studies under Wet Macular Degeneration, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 50. This study's 23 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bevacizumab
Outlook Therapeutics, Inc.